List view / Grid view


AstraZeneca advances tralokinumab to Phase III in severe asthma

14 August 2014 | By AstraZeneca

AstraZeneca announced the start of the Phase III programme for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by MedImmune, the company’s global biologics research and development arm...